Lack of therapeutic effect for ravulizumab emphasizes the unmet need for an extremely potent ALS treatment.

Published Date: 20 Nov 2023

USA: In a recent study, the safety and effectiveness of the complement C5 inhibitor ravulizumab in adult patients with was examined and published in JAMA Neurology.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot